Efficacy of carotid artery stenting on stroke prevention of octogenarians

2018 ◽  
Vol 173 ◽  
pp. 187-193 ◽  
Author(s):  
Reza Mohammadian ◽  
Ehsan Sharifipour ◽  
Aliakbar Taheraghdam ◽  
Reza Mansourizadeh ◽  
Davar Altafi ◽  
...  
2015 ◽  
Vol 17 (suppl A) ◽  
pp. A29-A33 ◽  
Author(s):  
A. Cremonesi ◽  
M. Mussardo ◽  
P. Sbarzaglia ◽  
B. Spagnolo ◽  
C. Cavazza ◽  
...  

2016 ◽  
Vol 47 (1) ◽  
pp. 185-192 ◽  
Author(s):  
Ahmed Elserwi ◽  
Talal Amer ◽  
Nermin Soliman ◽  
Ghada M. Gaballa ◽  
Ali H. Elmokadem

Angiology ◽  
2015 ◽  
Vol 67 (5) ◽  
pp. 408-410 ◽  
Author(s):  
Wesley S. Moore

The superiority of carotid endarterectomy (CEA) plus best medical treatment (BMT) over BMT alone for the management of patients with asymptomatic carotid stenosis is based on randomized controlled trials that recruited patients up to 30 years ago. Best medical treatment has improved considerably since that time with respect to stroke prevention. Furthermore, a new carotid intervention has emerged during the last 2 decades and has gradually become established, that is, carotid artery stenting (CAS). Consequently, the efficacy of current BMT alone needs to be compared not only with CEA plus BMT but also with CAS plus BMT to determine which strategy achieves the optimal stroke prevention rates. This article highlights the purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) 2 and discusses the issues that CREST-2 will hopefully provide answers to.


2017 ◽  
Vol 69 (18) ◽  
pp. 2266-2275 ◽  
Author(s):  
Partha Sardar ◽  
Saurav Chatterjee ◽  
Herbert D. Aronow ◽  
Amartya Kundu ◽  
Preethi Ramchand ◽  
...  

2011 ◽  
Vol 76 (6) ◽  
pp. S40-S59 ◽  
Author(s):  
Adnan H. Siddiqui ◽  
Sabareesh K. Natarajan ◽  
L. Nelson Hopkins ◽  
Elad I. Levy

2011 ◽  
Vol 77 (9) ◽  
pp. 1117-1130
Author(s):  
Charles B. Ross ◽  
Andrea E. Yancey ◽  
Kelly R. Byrnes ◽  
Erik J. Wayne ◽  
Amit J. Dwivedi ◽  
...  

The role of carotid artery stenting (CAS) as an alternative to carotid endarterectomy for the treatment of extracranial carotid occlusive disease for stroke prevention continues to evolve. Although technical and device refinements aimed at making CAS safer continue to this day, safety as measured by 30-day and 1-year outcomes has been the primary recipient of regulatory and practice attention. Relatively less emphasis has been placed on the incidence of recurrent stenosis after CAS and the efficacy of CAS in late stroke prevention. Data on late outcomes of CAS, including factors of potential influence, have been emerging and are addressed in this review.


2010 ◽  
Vol 363 (1) ◽  
pp. 80-82 ◽  
Author(s):  
Stephen M. Davis ◽  
Geoffrey A. Donnan

Sign in / Sign up

Export Citation Format

Share Document